Does UnitedHealthcare Cover GLP-1 Medications in 2026?

Introduction

UnitedHealthcare runs pharmacy benefits through OptumRx, both under the UnitedHealth Group corporate umbrella. That vertical integration shapes everything about GLP-1 coverage on UHC plans. The formulary, prior authorization criteria, step therapy rules, and appeals all flow through OptumRx.

UHC commercial plans in 2026 cover Wegovy® and Zepbound® on Tier 3 with prior authorization. Ozempic® and Mounjaro® are covered when prescribed for type 2 diabetes, also on Tier 3 with PA. The cardiovascular indication for Wegovy, FDA-approved in March 2024 after the SELECT trial (Lincoff et al. 2023, NEJM) showed 20 percent reduction in major adverse cardiovascular events, opened a separate pathway on most UHC plans. The OSA indication for Zepbound, FDA-approved in December 2024 after SURMOUNT-OSA, opened another.

What follows is a structured read of what UHC actually approves, what it denies, and where employer carve-outs sit.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

Which GLP-1 Medications Does UnitedHealthcare Cover?

UHC’s 2026 commercial formulary includes six GLP-1 medications: Wegovy (semaglutide for obesity and CVD), Zepbound (tirzepatide for obesity and OSA), Ozempic (semaglutide for type 2 diabetes), Mounjaro (tirzepatide for type 2 diabetes), Saxenda® (liraglutide for obesity), and Rybelsus® (oral semaglutide for type 2 diabetes).

Quick Answer: UnitedHealthcare runs pharmacy benefits through OptumRx; all PA, step therapy, and appeals flow through OptumRx first

Diabetes coverage is consistent across plans. Ozempic and Mounjaro are covered for type 2 diabetes with PA on virtually every UHC commercial plan. The PA requires recent A1C of 7.0 or higher and prior metformin trial unless contraindicated.

Obesity coverage is where variation appears. Whether UHC covers Wegovy or Zepbound depends on whether your specific employer plan opted into the weight-loss drug rider. Self-funded plans frequently exclude weight-loss medications even when the UHC formulary lists them.

What Is UnitedHealthcare’s 2026 Prior Authorization for Wegovy?

UHC’s 2026 commercial PA criteria for Wegovy require five elements: BMI of 30 or higher, or BMI 27 to 29.9 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, OSA, CVD), documentation of a structured weight management program for at least 6 months in the past 24 months, prescriber attestation that lifestyle changes alone have been inadequate, age 18 or older, and concurrent reduced-calorie diet and physical activity.

The cardiovascular indication added in 2024 has separate criteria: established CVD (prior MI, ischemic stroke, or symptomatic PAD) plus BMI of 27 or higher. The 6-month lifestyle program is typically waived under the CV pathway.

UHC does step therapy for Wegovy on some plans, requiring phentermine or Contrave first. Step therapy can be waived with documented contraindications or prior intolerance.

What Is UnitedHealthcare’s 2026 Prior Authorization for Zepbound?

Zepbound PA criteria mirror Wegovy in 2026, with the same BMI thresholds and 6-month program requirement. The SURMOUNT-1 trial (Jastreboff et al. 2022, NEJM) showed 20.9 percent weight loss at 72 weeks, the primary clinical reference OptumRx uses when evaluating medical necessity.

Some UHC plans require step therapy with Wegovy or an older agent before approving Zepbound. The step requirement can be waived with documented contraindication, intolerance, or insufficient response to the step drug.

For the OSA indication after SURMOUNT-OSA, UHC’s PA requires confirmed AHI of 15 or higher on polysomnography and BMI of 30 or higher. The 6-month lifestyle program is usually waived under the OSA pathway. SURMOUNT-OSA showed about a 27 events-per-hour AHI reduction in the treatment arm, which OptumRx reviewers cite when applying the OSA criteria.

Does UnitedHealthcare Cover Ozempic and Mounjaro?

Yes, for type 2 diabetes. Both are on formulary for nearly every UHC plan in 2026, typically Tier 2 or 3 with PA.

The PA for Ozempic requires type 2 diabetes diagnosis with ICD-10 documentation, A1C of 7.0 or higher (or 6.5 to 6.9 with prior metformin trial), and age 18 or older. The SUSTAIN trial program (multiple Lancet and NEJM publications 2017 through 2019) is the clinical reference.

Mounjaro PA is similar, with the SURPASS trial program as the reference. SURPASS-2 (Frias et al. 2021, NEJM) showed A1C reductions of 2.0 to 2.3 percentage points at the highest dose.

UHC does not cover off-label Ozempic or Mounjaro for weight loss. Without a type 2 diabetes diagnosis, these will be denied for obesity treatment.

What If I Have a UnitedHealthcare Medicare or Medicaid Plan?

UHC Medicare Part D plans cover Wegovy only for the cardiovascular indication after the March 2024 CMS coverage update. Wegovy is not covered for weight loss alone under Medicare. The PA requires established CVD with ICD-10 documentation and BMI of 27 or higher.

Zepbound is not covered for obesity under Medicare Part D as of 2026. CMS has not extended Part D coverage to the obesity indication for tirzepatide. Some UHC Medicare Advantage plans cover Zepbound for the OSA indication after the December 2024 approval, but this varies by plan and benefit rider.

UHC’s Medicaid managed care plans cover GLP-1s for type 2 diabetes nationwide. Obesity coverage varies by state. UHC Medicaid plans follow state-level coverage rules.

Key Takeaway: Wegovy and Zepbound coverage depends on whether the employer plan opted into the weight-loss drug rider

What About UHC Self-funded Employer Plans?

UHC administers many self-funded employer plans through ASO arrangements. The benefit design comes from the employer, not UHC. A self-funded employer can carve out weight-loss drugs entirely, leaving the UHC formulary intact but with a benefit exclusion.

The carve-out applies to obesity coverage in most cases. The cardiovascular indication for Wegovy and the OSA indication for Zepbound may be covered separately because they are not obesity-coverage line items. Check with HR or the plan document for indication-specific coverage.

Diabetes coverage for Ozempic and Mounjaro is rarely carved out because diabetes is a near-universal benefit on commercial plans.

What If UnitedHealthcare Denies My GLP-1 Prescription?

Pull your OptumRx adverse determination letter and find the denial reason code. The most common codes are PA-NOT-MET, NF (non-formulary), STEP-REQ (step therapy required), BMI-NOT-MET, and EMP-EXCL (employer carve-out).

For PA-NOT-MET denials, file a level-1 internal appeal with OptumRx within 180 days. Include a Letter of Medical Necessity from your prescriber citing STEP 1 (Wilding et al. 2021, NEJM) for Wegovy or SURMOUNT-1 (Jastreboff et al. 2022, NEJM) for Zepbound. Add documentation of the 6-month weight management program with dates.

For employer carve-outs, the appeal pathway is closed because the benefit comes from the plan document. Cash-pay options become primary. Compounded semaglutide through a licensed telehealth platform like TrimRx is one route, with a free assessment quiz to determine eligibility.

How Much Do GLP-1 Medications Cost with UnitedHealthcare?

With PA approved on Tier 3, expect a copay of $40 to $100 per month for commercial plans, depending on benefit design. High-deductible plans require the full negotiated price (around $900 to $1,000 per month) until the deductible is met.

Without coverage, brand-name Wegovy lists at approximately $1,349 per month. The Novo Nordisk NovoCare savings card can bring eligible commercially-insured patients to $0 to $25 per month, and the NovoCare Pharmacy direct cash program offers Wegovy at about $499 per month for cash-pay patients.

Brand-name Zepbound lists at approximately $1,059 per month. The Eli Lilly LillyDirect cash pharmacy offers Zepbound single-dose vials at $349 to $499 per month, available to commercially-insured patients without coverage and to cash-pay patients.

What Is the Appeal Process Timeline?

A standard level-1 internal appeal takes 30 days. A level-2 internal appeal takes another 30 days. External review through your state insurance commissioner is usually 45 days but can be expedited to 72 hours with documented urgent medical need.

The full timeline through every appeal level: roughly 4 to 5 months from initial denial to a final external review decision. Expedited appeals can compress this to 10 to 14 days.

During the appeal, options include paying cash with a plan for retroactive reimbursement if the appeal succeeds, using the manufacturer savings programs, or starting a personalized treatment plan with a compounded GLP-1 through a telehealth provider while the review is pending.

Bottom line: UHC Medicare Part D covers Wegovy only for the cardiovascular indication, not weight loss alone

FAQ

Does UnitedHealthcare Cover Wegovy for Weight Loss in 2026?

Most UHC commercial plans cover Wegovy for obesity with PA if you meet BMI criteria and document a 6-month weight management program. Coverage depends on whether your specific employer plan opted into the weight-loss drug rider. About 55 to 65 percent of commercial groups under UHC cover Wegovy for obesity.

Why Does UnitedHealthcare Cover Ozempic but Not Wegovy on My Plan?

Ozempic is covered for type 2 diabetes, a near-universal benefit on commercial plans. Wegovy is covered for obesity, which many self-funded employer plans exclude through a weight-loss drug carve-out. Same active ingredient, different FDA indications, different coverage logic.

Does UHC Cover Compounded Semaglutide or Tirzepatide?

No. UHC and most other commercial insurers do not cover compounded GLP-1 medications because they are not FDA-approved finished products. Compounded semaglutide is paid out of pocket through licensed 503A pharmacies, with prescriptions written by telehealth providers like TrimRx after a clinical assessment.

How Do I Check If My UHC Plan Covers Wegovy?

Log into your UHC member portal or the OptumRx app and search the formulary for Wegovy. Look at the tier and check PA, step therapy, and quantity limits. If formulary search isn’t available, call the pharmacy benefit number on the back of your card and ask about Wegovy coverage and PA criteria.

Does UnitedHealthcare Cover Zepbound for Sleep Apnea?

After the FDA approved Zepbound for moderate-to-severe OSA in December 2024, most UHC plans added an OSA coverage pathway. PA requires confirmed AHI of 15 or higher on polysomnography and BMI of 30 or higher. The 6-month weight management program requirement is usually waived under the OSA indication.

What Is the Appeal Success Rate for UHC GLP-1 Denials?

CMS data from 2023 shows roughly 41 percent of commercial denials are overturned on a level-1 internal appeal when new documentation is submitted. External review approval rates run around 50 percent for prescription drug denials.

Can I Get Wegovy Through UHC If I Have Prediabetes but Not Diabetes?

Prediabetes alone is not a qualifying comorbidity under most UHC PA criteria. You would need BMI of 30 or higher to qualify on BMI alone, or a documented comorbidity like hypertension or dyslipidemia plus BMI of 27 or higher. Some plans accept metabolic syndrome diagnosis as a qualifying comorbidity.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.